For research use only. Not for therapeutic Use.
3BDO (Cat No.:I012918) is a butyrolactone derivative with diverse effects on cellular processes. It can target FKBP1A (FK506-binding protein 1A) and activate the mTOR (mammalian target of rapamycin) signaling pathway, leading to the inhibition of autophagy in human umbilical vein endothelial cells (HUVECs). Additionally, 3BDO displays the capability to inhibit apoptosis induced by oxidized low-density lipoprotein (ox-LDL). These properties suggest that 3BDO may hold potential as a therapeutic agent in conditions related to autophagy dysregulation and apoptotic cell death.
| Catalog Number | I012918 |
| CAS Number | 890405-51-3 |
| Molecular Formula | C₁₈H₁₇NO₅ |
| Purity | ≥95% |
| Target | Autophagy |
| Solubility | DMSO |
| IUPAC Name | 3-benzyl-5-[(2-nitrophenoxy)methyl]oxolan-2-one |
| InChI | InChI=1S/C18H17NO5/c20-18-14(10-13-6-2-1-3-7-13)11-15(24-18)12-23-17-9-5-4-8-16(17)19(21)22/h1-9,14-15H,10-12H2 |
| InChIKey | AXPZIVKEZRHGAS-UHFFFAOYSA-N |
| SMILES | C1C(C(=O)OC1COC2=CC=CC=C2[N+](=O)[O-])CC3=CC=CC=C3 |
| Reference | [1]. Ge D, et al. Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cells. Autophagy. 2014 Jun;10(6):957-71.<br>[2]. Peng N, et al. An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E⁻/⁻ mice. Sci Rep. 2014 Jul 1;4:5519. |
